Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Vitaxel Group Ltdg081947_ex32-2.htm
EX-32.1 - EXHIBIT 32.1 - Vitaxel Group Ltdg081947_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - Vitaxel Group Ltdg081947_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - Vitaxel Group Ltdg081947_ex31-1.htm
EX-21.1 - EXHIBIT 21.1 - Vitaxel Group Ltdg081947_ex21-1.htm
10-K - 10-K - Vitaxel Group Ltdg081947_10k.htm

Exhibit 4.1

 

Description of Common Stock

 

The following summary description is based on the provisions of our Amended and Restated Articles of Incorporation (the “Articles of Incorporation”), our Bylaws, (the “Bylaws”), and the applicable provisions of the Nevada Revised Statutes (the “NRS”). This information may not be complete in all respects and is qualified entirely by reference to the provisions of our Articles of Incorporation, our Bylaws and the NRS. Our Articles of Incorporation and our Bylaws are filed as exhibits to this Annual Report on Form 10-K.

General

Our authorized capital stock consists of 70,000,000 shares of Common Stock, and 1,000,000 shares of undesignated preferred stock, $0.0001 par value per share (“Preferred Stock”).

Common Stock

Dividend Rights

Subject to preferences that may apply to shares of Preferred Stock outstanding at the time, the holders of outstanding shares of our Common Stock are entitled to receive dividends out of funds legally available at the times and in the amounts that our board of directors may determine.

Voting Rights

Each holder of our Common Stock is entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders. Cumulative voting for the election of directors is not provided for in our articles of incorporation, which means that the holders of a majority of our shares of Common Stock voted can elect all of the directors then standing for election.

Preemptive or Similar Rights

Our Common Stock is not entitled to preemptive rights and is not subject to conversion or redemption. The rights of the holders of our Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our Preferred Stock that our board of directors may designate and issue in the future.

Liquidation Rights

Upon our liquidation, dissolution, or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our Common Stock and any participating Preferred Stock outstanding at that time after payment of liquidation preferences, if any, on any outstanding shares of Preferred Stock and payment of other claims of creditors.

 

Preferred Stock

Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to 1,000,000 shares of our Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each series, to fix the designation, powers, preferences, and rights of the shares of each series and any of its qualifications, limitations, or restrictions, in each case without further action by our stockholders. Our board of directors can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of shares of that series then outstanding, unless approved by the affirmative vote of the holders of a majority of our capital stock entitled to vote, or such other vote as may be required by the certificate of designation establishing the series. Our board of directors may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the Common Stock. 

The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring, or preventing a change in our control and might adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock.